Solid Biosciences (SLDB) Cash from Operations (2017 - 2024)
Historic Cash from Operations for Solid Biosciences (SLDB) over the last 8 years, with Q4 2024 value amounting to -$29.6 million.
- Solid Biosciences' Cash from Operations fell 4236.66% to -$29.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$100.0 million, marking a year-over-year decrease of 619.24%. This contributed to the annual value of -$100.0 million for FY2024, which is 619.24% down from last year.
- Latest data reveals that Solid Biosciences reported Cash from Operations of -$29.6 million as of Q4 2024, which was down 4236.66% from -$23.7 million recorded in Q3 2024.
- In the past 5 years, Solid Biosciences' Cash from Operations ranged from a high of $1.3 million in Q4 2020 and a low of -$34.5 million during Q4 2022
- Its 5-year average for Cash from Operations is -$21.3 million, with a median of -$21.1 million in 2021.
- As far as peak fluctuations go, Solid Biosciences' Cash from Operations surged by 10615.2% in 2020, and later tumbled by 169709.26% in 2021.
- Quarter analysis of 5 years shows Solid Biosciences' Cash from Operations stood at $1.3 million in 2020, then tumbled by 1697.09% to -$20.9 million in 2021, then plummeted by 65.18% to -$34.5 million in 2022, then soared by 39.61% to -$20.8 million in 2023, then crashed by 42.37% to -$29.6 million in 2024.
- Its Cash from Operations stands at -$29.6 million for Q4 2024, versus -$23.7 million for Q3 2024 and -$21.5 million for Q2 2024.